Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines

References

• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865–75
   PubMed Web of Science ®Google Scholar
• Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001; 19: 379–82
   PubMed Web of Science ®Google Scholar
• Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419–26
   PubMed Web of Science ®Google Scholar
• Liu JH, Yang MH, Fan FS, Yen CC, Wang WS, Chang YH, et al. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 2001; 57: 650–4
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408–17
   PubMed Web of Science ®Google Scholar
• Rini BI. New approaches in advanced renal cell carcinoma. Urol Oncol 2005; 23: 65–6
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24
   PubMed Web of Science ®Google Scholar
• Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004; 10: 6397–403s
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol 2004; 22: 4233–4
   PubMedGoogle Scholar
• Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63
   PubMed Web of Science ®Google Scholar
• Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220–9
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998; 32: 129–38
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russel G, et al. Bisphosphonates – mechanisms of action in multiple myeloma. Acta Oncol 2000; 39: 829–35
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21
   PubMed Web of Science ®Google Scholar
• Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521–8; discussion 528–9.
   PubMed Web of Science ®Google Scholar
• Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8
   PubMed Web of Science ®Google Scholar
• Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295–306
   PubMed Web of Science ®Google Scholar
• Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294–7
   PubMed Web of Science ®Google Scholar
• Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170: 246–52
   PubMed Web of Science ®Google Scholar
• Green J. Bisphosphonates: preclinical review. Oncologist 2004; 9(Suppl 4)3–13
   PubMed Web of Science ®Google Scholar
• Mönkkönen H, Lehenkari PP, Kellinsalmi M, Hassinen IE, Auriola S, Vepsäläinen J, et al. A new mechanism of action for bisphosphonates: Apppi dedicated cytotoxicity of N-BPs. Bone 2004;34:S66–7.
   Google Scholar
• Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177–85
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–34
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68
   PubMed Web of Science ®Google Scholar
• Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005; 44: 644–50
   PubMed Web of Science ®Google Scholar
• Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003; 26: S92–7
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modianom JF, et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer 2007; 6: 16
   PubMedGoogle Scholar
• Nygren P, Larsson R. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 1991; 48: 598–604
   PubMed Web of Science ®Google Scholar
• Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006; 66: 2785–93
   PubMed Web of Science ®Google Scholar
• Bivén K, Erdal H, Hägg M, Ueno T, Zhou R, Lynch M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003; 8: 263–8
   PubMed Web of Science ®Google Scholar
• Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56: 399–404
   PubMed Web of Science ®Google Scholar
• Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 2006; 176: 2255–61
   PubMed Web of Science ®Google Scholar